An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD).
The purpose of this study is to characterize the long-term safety and efficacy of amlitelimab in treated participants with age ≥12 years old with moderate to severe AD.
The study duration per participant will be up to 284 weeks, including:
The planned number of visits will be 35 visits.
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Birmingham, Alabama 35209, United States
Centennial, Colorado 80112, United States
Cape Coral, Florida 33991, United States
Miami, Florida 33143, United States
Livonia, Michigan 48152, United States
Waterford, Michigan 48328, United States
Philadelphia, Pennsylvania 19104, United States
San Antonio, Texas 78218, United States
Burlington, Wisconsin 53105, United States
Salvador, Estado de Bahia 41820-020, Brazil
Curitiba, Paraná 80060-900, Brazil
Porto Alegre, Rio Grande do Sul 90020-090, Brazil
Ribeirão Preto, São Paulo 14049-900, Brazil
São José do Rio Preto, São Paulo 15090-000, Brazil
Rio de Janeiro, 22470-220, Brazil